Micofenolato Mofetile Aurobindo

Mycophenolate Mofetil, the active ingredient in Micofenolato Mofetile, is an immunosuppressant presented as an oral formulation for oral use. It is employed to prevent acute rejection in solid‑organ transplantation and to treat lupus nephritis and other autoimmune conditions where immune suppression is required.

GNH USA supplies Micofenolato Mofetile as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution, including batch release certificates and stability data.

Mycophenolate Mofetil is used to suppress immune responses in several transplant and autoimmune contexts. - Kidney transplantation: helps prevent acute graft rejection. - Heart transplantation: reduces incidence of rejection episodes. - Liver transplantation: supports maintenance immunosuppression. - Lupus nephritis: contributes to disease control and renal protection. - Other solid organ transplants: provides long‑term immunosuppression.

Mycophenolate Mofetil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Hematologic changes: anemia, leukopenia or thrombocytopenia. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Malignancy: increased risk of lymphoproliferative disorders or skin cancers. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Bone marrow failure: aplastic anemia or pancytopenia.

When prescribing Mycophenolate Mofetil, clinicians should consider several precautionary measures to minimize risk. - Pregnancy: contraindicated; teratogenic risk requires effective contraception. - Renal impairment: dose adjustment may be needed; monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Infection risk: screen for latent infections and vaccinate before therapy. - Blood monitoring: regular complete blood counts to detect cytopenias. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture.

Mycophenolate Mofetil interacts with several agents that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Antimetabolites (e.g., azathioprine): additive bone marrow suppression. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce drug exposure. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours. - ACE inhibitors or ARBs: may exacerbate renal dysfunction; monitor kidney function. - Vaccines (inactivated): generally safe but monitor immune response.